Skip to content

Regorafenib as Second-Line Versus Later-Line Therapy in Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study with Exploratory Analysis of Prior Immune Checkpoint Inhibitor Exposure

Sep 2026 · Targeted oncology · Vol 21, pp. 761 - 773 · 0 citations · 30 references
Medicine
View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.